The estimated Net Worth of Ronit Satchi Fainaro is at least $1.9 Milion dollars as of 15 June 2024. Ronit Fainaro owns over 21,108 units of Teva- Pharmaceutical Industries stock worth over $1,585,455 and over the last 6 years he sold TEVA stock worth over $0. In addition, he makes $310,424 as Independent Director at Teva- Pharmaceutical Industries.
Sign up
Ronit Fainaro TEVA stock SEC Form 4 insiders trading
Ronit has made over 6 trades of the Teva- Pharmaceutical Industries stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 21,108 units of TEVA stock worth $379,100 on 15 June 2024.
The largest trade he's ever made was exercising 21,108 units of Teva- Pharmaceutical Industries stock on 15 June 2024 worth over $379,100. On average, Ronit trades about 6,748 units every 113 days since 2018. As of 15 June 2024 he still owns at least 88,277 units of Teva- Pharmaceutical Industries stock.
You can see the complete history of Ronit Fainaro stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ronit Satchi-Fainaro biography
Professor Ronit Satchi-Fainaro serves as Independent Director of the Company. Prof. Satchi-Fainaro has been a professor at Tel Aviv University since 2015, where she has served as Head of the Cancer Research and Nanomedicine Laboratory since 2006, Chair of the Department of Physiology and Pharmacology at the Sackler Faculty of Medicine since 2014, Chair of The Kurt and Herman Lion Cathedra in Nanosciences and Nanotechnologies since 2017 and a member of the Preclinical Dean’s Committee since 2015. She served as President of The Israel Controlled Release Society from 2010 to 2014. In 2003, she was appointed Instructor in Surgery at Children’s Hospital in Boston and Harvard Medical School, where she has been a Visiting Professor since 2005. Prof. Satchi-Fainaro also serves as a consultant to several biotech and pharmaceutical companies, and is a member of the scientific advisory board of the Blavatnik Center for Drug Discovery, The Israel Cancer Association and Vall d’Hebron University Hospital Foundation—Research Institute. She is also a member of several editorial boards of scientific journals. Prof. Satchi-Fainaro received her B.Pharm. from the Hebrew University in Jerusalem in 1995 and her Ph.D. in Polymer Chemistry and Cancer Nanomedicine from the University of London in 1999.
What is the salary of Ronit Fainaro?
As the Independent Director of Teva- Pharmaceutical Industries, the total compensation of Ronit Fainaro at Teva- Pharmaceutical Industries is $310,424. There are 18 executives at Teva- Pharmaceutical Industries getting paid more, with Kaare Schultz having the highest compensation of $11,596,600.
How old is Ronit Fainaro?
Ronit Fainaro is 47, he's been the Independent Director of Teva- Pharmaceutical Industries since 2018. There are 27 older and 1 younger executives at Teva- Pharmaceutical Industries. The oldest executive at Teva- Pharmaceutical Industries Ltd. is Gerald Lieberman, 73, who is the Independent Director.
What's Ronit Fainaro's mailing address?
Ronit's mailing address filed with the SEC is C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, L3, 6944020.
Insiders trading at Teva- Pharmaceutical Industries
Over the last 7 years, insiders at Teva- Pharmaceutical Industries have traded over $31,332,399 worth of Teva- Pharmaceutical Industries stock and bought 967,500 units worth $16,473,820 . The most active insiders traders include Sol J Barer, Tal Zvi Zaks oraz Roberto Mignone. On average, Teva- Pharmaceutical Industries executives and independent directors trade stock every 9 days with the average trade being worth of $636,538. The most recent stock trade was executed by Varda Shalev on 2 September 2024, trading 12,872 units of TEVA stock currently worth $231,181.
What does Teva- Pharmaceutical Industries do?
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
What does Teva- Pharmaceutical Industries's logo look like?
Complete history of Ronit Fainaro stock trades at Teva- Pharmaceutical Industries
Teva- Pharmaceutical Industries executives and stock owners
Teva- Pharmaceutical Industries executives and other stock owners filed with the SEC include:
-
Kaare Schultz,
President, Chief Executive Officer, Director -
Kare Schultz,
Pres, CEO & Director -
Mark Sabag,
Executive Vice President, Chief Human Resources Officer and Global Communications and Brand -
Hafrun Fridriksdottir,
Executive Vice President - Global R&D -
Brendan O'Grady,
Executive Vice President - North America Commercial -
Gianfranco Nazzi,
Executive Vice President - International Markets Commercial -
Dr. Hafrun Fridriksdottir,
Exec. VP of Global R&D -
Gianfranco Nazzi,
Exec. VP of International Markets Commercial -
Eric Drape,
Exec. VP of Global Operations -
Eliyahu Sharon Kalif,
Exec. VP & CFO -
Sol Barer,
Independent Chairman of the Board -
Nechemia Peres,
Independent Director -
Gerald Lieberman,
Independent Director -
Amir Elstein,
Independent Director -
Roberto Mignone,
Independent Director -
Rosemary Crane,
Independent Director -
Jean-Michel Halfon,
Independent Director -
Perry Nisen,
Independent Director -
Ronit Satchi-Fainaro,
Independent Director -
Eliyahu Kalif,
Chief Financial Officer, Executive Vice President -
Kevin Mannix,
Senior Vice President, Investor Relations -
Janet Vergis,
Independent Director -
Abbas Hussain,
Independent Director -
David Stark,
Executive Vice President, Chief Legal Officer -
Eric Drape,
Executive Vice President - Global Operations -
Sven Dethlefs,
Executive Vice President - Global Marketing & Portfolio -
Richard Daniell,
Executive Vice President - European Commercial -
Eli Shani,
Exec. VP of Global Marketing & Portfolio -
Galia Inbar,
Exec. VP, Chief HR Officer and Head of Global Communications, Brand & ESG -
David M. Stark,
Exec. VP & Chief Legal Officer -
Amir Weiss,
Sr. VP & Chief Accounting Officer -
Lori Queisser,
Sr. VP & Global Compliance Officer -
Andrew J. Weil CPA,
Chief Accounting Officer -
Eric Drapé,
Exec. VP of Global Operations -
Iris Beck Codner,
EVP Global Brand&Communication -
Kare Schultz,
President and CEO -
Michael James Mc Clellan,
EVP, Chief Financial Officer -
Notaristefani Carlo De,
Executive VP Global Operations -
Placid Jover,
See "Remarks" -
Deborah A Griffin,
Chief Accounting Officer -
Varda Shalev,
-
Dan S Suesskind,
Director -
Murray A Goldberg,
Director -
Dov Bergwerk,
Acting Chief Legal Officer -
David R. Mc Avoy,
EVP, Chief Legal Officer -
Andrew Weil,
Chief Accounting Officer -
Galia Inbar,
See "Remarks" -
Eli Shani,
EVP,Global Marketing&Portfolio -
Angus Grant,
EVP, Business Development -
Eric A Hughes,
See "Remarks" -
Vikki L Conway,
See "Remarks" -
Christine Fox,
EVP, Head of U.S. Commercial -
Amir Weiss,
Chief Accounting Officer -
Richard D Francis,
President and CEO -
Matthew Shields,
EVP, Global Operations -
Tal Zvi Zaks,